Cidara Other Current Liab from 2010 to 2025

CDTX Stock  USD 21.32  0.71  3.22%   
Cidara Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 9.3 M in 2025. During the period from 2010 to 2025, Cidara Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.76 and arithmetic mean of  6,918,290. View All Fundamentals
 
Other Current Liabilities  
First Reported
2013-12-31
Previous Quarter
13.5 M
Current Value
18.3 M
Quarterly Volatility
5.5 M
 
Yuan Drop
 
Covid
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14.7 M or Other Operating Expenses of 186.2 M, as well as many indicators such as Price To Sales Ratio of 141, Dividend Yield of 0.0 or PTB Ratio of 1.1. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Cidara Therapeutics over the last few years. It is Cidara Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Cidara Other Current Liab Regression Statistics

Arithmetic Mean6,918,290
Geometric Mean2,170,668
Coefficient Of Variation95.57
Mean Deviation5,471,826
Median6,828,000
Standard Deviation6,611,989
Sample Variance43.7T
Range19.1M
R-Value0.87
Mean Square Error11.5T
R-Squared0.76
Significance0.000012
Slope1,206,961
Total Sum of Squares655.8T

Cidara Other Current Liab History

20259.3 M
202418.3 M
202319.2 M
202212.6 M
202113.9 M
202011.2 M
20197.7 M

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities18.3 M9.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.